Published in Gut on November 07, 2012
Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med (2017) 2.08
Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer (2014) 1.00
Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One (2013) 0.98
miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis. World J Gastroenterol (2013) 0.97
RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One (2014) 0.94
Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics (2014) 0.87
Microarray analysis reveals global modulation of endogenous retroelement transcription by microbes. Retrovirology (2014) 0.86
Emerging significance of NLRs in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.86
Reduced expression of aquaporins in human intestinal mucosa in early stage inflammatory bowel disease. Clin Exp Gastroenterol (2015) 0.84
Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res (2014) 0.84
The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation. Am J Pathol (2015) 0.83
A key requirement for CD300f in innate immune responses of eosinophils in colitis. Mucosal Immunol (2016) 0.80
Lipid antigens in immunity. Biol Chem (2014) 0.79
Multivariate inference of pathway activity in host immunity and response to therapeutics. Nucleic Acids Res (2014) 0.79
Mucosal transcriptomics implicates under expression of BRINP3 in the pathogenesis of ulcerative colitis. Inflamm Bowel Dis (2014) 0.77
Leukocyte-epithelial interactions and mucosal homeostasis. Toxicol Pathol (2013) 0.76
Epithelial IL-1R2 acts as a homeostatic regulator during remission of ulcerative colitis. Mucosal Immunol (2015) 0.76
Transcriptome profiling of human ulcerative colitis mucosa reveals altered expression of pathways enriched in genetic susceptibility loci. PLoS One (2014) 0.75
Functional and protein‑protein interaction network analysis of colorectal cancer induced by ulcerative colitis. Mol Med Rep (2015) 0.75
Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease. EMBO Mol Med (2017) 0.75
Revealing potential molecular targets bridging colitis and colorectal cancer based on multidimensional integration strategy. Oncotarget (2015) 0.75
A Mucosal and Cutaneous Chemokine Ligand for the Lymphocyte Chemoattractant Receptor GPR15. Front Immunol (2017) 0.75
The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol (2017) 0.75
Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis. Exp Ther Med (2017) 0.75
CAMK2γ in intestinal epithelial cells modulates colitis-associated colorectal carcinogenesis via enhancing STAT3 activation. Oncogene (2017) 0.75
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38
Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet (2002) 14.34
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell (2009) 3.66
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc (2011) 2.96
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol (2009) 2.53
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol (2005) 2.48
Small molecule integrin antagonists that bind to the beta2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity (2003) 2.34
The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J Cell Biol (2004) 2.22
Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis (2012) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol (2007) 1.95
Endothelial cells proactively form microvilli-like membrane projections upon intercellular adhesion molecule 1 engagement of leukocyte LFA-1. J Immunol (2003) 1.95
Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nat Struct Biol (2003) 1.92
Magnetic resonance imaging for evaluation of Crohn's disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis (2010) 1.91
Importance of force linkage in mechanochemistry of adhesion receptors. Biochemistry (2006) 1.87
Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology (2006) 1.71
Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol (2006) 1.71
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol (2003) 1.60
Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med (2005) 1.57
Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab (2003) 1.55
Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. Proc Natl Acad Sci U S A (2004) 1.49
CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med (2004) 1.49
Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial. Gastroenterology (2008) 1.46
[Organization and functioning model of biomedical research structures. Situation and future challenges]. Med Clin (Barc) (2008) 1.46
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther (2011) 1.40
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol (2007) 1.38
Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg (2005) 1.33
Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis (2013) 1.31
Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukoc Biol (2004) 1.28
Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One (2010) 1.25
Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol (2009) 1.23
AL-57, a ligand-mimetic antibody to integrin LFA-1, reveals chemokine-induced affinity up-regulation in lymphocytes. Proc Natl Acad Sci U S A (2006) 1.20
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys (2003) 1.19
The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1. J Immunol (2004) 1.18
Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci U S A (2002) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol (2006) 1.15
Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology (2003) 1.13
Endoscopic ultrasound-guided fine needle aspiration: predictive factors of accurate diagnosis and cost-minimization analysis of on-site pathologist. Gastroenterol Hepatol (2007) 1.12
A prospective trial comparing wireless capsule endoscopy and barium contrast series for small-bowel surveillance in hereditary GI polyposis syndromes. Gastrointest Endosc (2005) 1.10
Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab (2006) 1.08
Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood (2004) 1.08
A small molecule agonist of an integrin, alphaLbeta2. J Biol Chem (2006) 1.04
TNF alpha production to TLR2 ligands in active IBD patients. Clin Immunol (2006) 1.02
Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol (2007) 1.00
The role of P-selectin in experimental colitis as determined by antibody immunoblockade and genetically deficient mice. J Leukoc Biol (2002) 1.00
Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease. J Crohns Colitis (2011) 0.99
Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol (2009) 0.99
Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1. J Leukoc Biol (2006) 0.98
PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas. Genomics (2005) 0.96
Endoscopic requirements of colorectal cancer screening programs in average-risk population. Estimation according to a Markov model. Gastroenterol Hepatol (2008) 0.96
Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. Inflamm Bowel Dis (2008) 0.94
Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography- guided fine-needle aspiration biopsy. Clin Cancer Res (2004) 0.93
Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg (2007) 0.93
Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer (2011) 0.93
Transcriptional regulation by poly(ADP-ribose) polymerase-1 during T cell activation. BMC Genomics (2008) 0.92
Imaging indexes of activity and severity for Crohn's disease: current status and future trends. Abdom Imaging (2012) 0.92
Effect of cyclosporin A on cell adhesion molecules and leukocyte-endothelial cell interactions in experimental colitis. Inflamm Bowel Dis (2004) 0.91
Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis (2013) 0.91
A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut (2012) 0.90
ARHGAP8 is a novel member of the RHOGAP family related to ARHGAP1/CDC42GAP/p50RHOGAP: mutation and expression analyses in colorectal and breast cancers. Gene (2004) 0.90
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis (2012) 0.90
Down-regulation of endothelial adhesion molecules and leukocyte adhesion by treatment with superoxide dismutase is beneficial in chronic immune experimental colitis. Inflamm Bowel Dis (2005) 0.89
Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer. Carcinogenesis (2007) 0.89
Role of 3.0-T MR colonography in the evaluation of inflammatory bowel disease. Radiographics (2009) 0.89
Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis (2013) 0.89
Association of Helicobacter pylori-related distal gastric cancer with the HLA class II gene DQB10602 and cagA strains in a southern European population. Helicobacter (2005) 0.89
Endoscopic ultrasonography in patients with large gastric folds at endoscopy and biopsies negative for malignancy: predictors of malignant disease and clinical impact. Am J Gastroenterol (2006) 0.88
Impact of mass screening for gluten-sensitive enteropathy in working population. World J Gastroenterol (2009) 0.87
Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis (2009) 0.87
The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and its expression is regulated by activin A. J Immunol (2012) 0.87